💊

Drugs Recalls

Prescription and over-the-counter medications

17,302 Total Recalls

CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodiethylamine (NDEA) contained in the API used to manufacture the product above the interim acceptable daily intake level of 0.083 parts per million.

Nov 1, 2018 Prescription Drugs View Details →

CGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodimethylamine (NDEA) in product.

Oct 29, 2018 Prescription Drugs Nationwide View Details →

CGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodimethylamine (NDEA) in product.

Oct 29, 2018 Prescription Drugs Nationwide View Details →

Presence of foreign substance: Product found to contain metal particles.

Nov 6, 2018 Prescription Drugs Nationwide View Details →

CGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodimethylamine (NDEA) in product.

Oct 29, 2018 Prescription Drugs Nationwide View Details →

Cross contamination with other products: This sub-recall is being initiated in support of the recall by the manufacturer (Sandoz) dated 11/1/18, which included lots that were repackaged by American Health Packaging. Sandoz stated that "These lots are being recalled due to the potential presence of unrelated ingredients (i.e. traces of active ingredients of Benazepril, Haloperidol and Perphenazine), which were identified through a manufacturing investigation."

Nov 9, 2018 Prescription Drugs Nationwide View Details →